<DOC>
	<DOCNO>NCT00081536</DOCNO>
	<brief_summary>This study Phase I/II study . In Phase I study , objective determine maximum tolerate dose ( MTD ) combination therapy Aroplatin capecitabine subject unresectable , local recurrence distant metastases colorectal cancer refractory 5-FU/leucovorin irinotecan . In Phase II , primary objective evaluate response proportion duration Aroplatin/capecitabine therapy . Secondary objective evaluate frequency severity adverse event .</brief_summary>
	<brief_title>Aroplatin Capecitabine Patients With Advanced Colorectal Cancer Resistant Standard Therapies</brief_title>
	<detailed_description>Phase I Primary Objective : - Determine MTD Aroplatin/capecitabine subject unresectable local recurrence distant metastases colorectal cancer refractory 5-FU/LV irinotecan . Phase II Primary Objective : - Evaluate response proportion duration Aroplatin/capecitabine therapy . Phase II Secondary Objective : - Evaluate frequency adverse event .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>bis-neodecanoato-1,2-diaminocyclohexaneplatinum ( II )</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm colorectal cancer : unresectable local recurrence distant metastasis ; Measurable disease ( RECIST criterion ) ; Refractory 5FU / leucovorin irinotecan describe ; No prior therapy oxaliplatin , platinum capecitabine ; ECOG score 02 ( Karnofsky 10070 % ) ; Life expectancy great equal 5 month ; Adequate hematopoietic , liver renal function ; Women childbearing potential practice adequate contraception ; Signed write informed consent ; Subjects must willing follow course treatment/observation followup . Refractory metastatic colorectal cancer The following subject regard refractory treatment : Those progression receive 5FU/LV/irinotecan ; Those progression irinotecan prior 5FU/LV treatment ; Progression within six month adjuvant 5FU/LV/irinotecan ; Progression within six month adjuvant 5FU/LV follow progression irinotecan Subjects must receive least one commonly use 5FU/leucovorin irinotecan regimen . Prior adjuvant therapy allow include 5FU/leucovorin fluoropyrimidines except capecitabine irinotecan . Exclusion criterion : Previously diagnose brain metastasis symptomatic require active therapy ; Other cancer within last five year , exception adequately treat conebiopsied situ carcinoma cervix uteri basal squamous cell carcinoma skin ; Concurrent chemotherapy immunotherapy ; Prior therapy colorectal cancer within one month admission present study ; Primary secondary immunodeficiency use corticosteroid immunosuppressive medication ; Any serious concomitant medical mental illness require intense therapy interfere participation study ; Women must pregnant breastfeeding ; No participation clinical trial involve investigational drug within 1 month enrollment present study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Colorectal Carcinoma</keyword>
	<keyword>Colorectal Tumor</keyword>
	<keyword>Neoplasms , Colorectal</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Refractory</keyword>
</DOC>